WP7 Subgroup 2 is pleased to announce the publication of the Position paper on how to decide on the appropriate study design for primary research arising from HTA reports.
Continuous improvement of the HTA Core Model – Version 3.0 has been made available as a public draft.
Meeting minutes from the EUnetHTA-EMA meeting that took place 8 May 2015 in London, UK, is now available.
We are pleased to announce that as of today the Draft Project Plan regarding the production of a Rapid Relative Effectiveness Assessment of new pharmaceuticals for the treatment of chronic hepatitis C by Work Package 5 has entered the public consultation phase.
The Joint Assessment on "Vorapaxar (ZONTIVITY™) for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infection (MI)" is now available